Compare State Street SPDR S&P Biotech ETF (XBI) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.14, while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| XBI | XLY | |
|---|---|---|
Sector | Broad Market / Factor | — |
52-Week High | $164.28 | $124.52 |
52-Week Low | $86.92 | $105.64 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
XLY trades at $118.02, down 1.38% today, with a bullish technical signal from moving averages but overbought RSI readings. Analyst consensus is unanimously positive, with a 100% buy rating. The ETF focuses on consumer discretionary stocks, benefiting from economic trends favoring the sector.
Outlook remains favorable due to strong analyst support and sector momentum, though overbought conditions and consumer spending sensitivity pose near-term risks. Long-term growth hinges on sustained economic strength and discretionary demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
